Asterias develops regenerative medicines for neurology, oncology, cardiology, ophthalmology, orthopedics and metabolic diseases... Read more
Asterias develops regenerative medicines for neurology, oncology, cardiology, ophthalmology, orthopedics and metabolic diseases... Read more
Est. Annual Revenue
Est. Employees
News
Mar 14, 2019
BioPortfolio
Asterias: BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Feb 14, 2019
streetinsider
Press Release: Asterias : BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias
Jan 24, 2019
BioPortfolio
Asterias: Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 12a Clinical Trial
Nov 27, 2018
GlobeNewswire
Press Release: Asterias : Asterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small Cell Lung Cancer
Nov 14, 2018
BioPortfolio
Asterias: BioTime Acquires Two ClinicalStage Cell Therapy Product Candidates Addressing Significant Unmet Needs in Spinal Cord Injury and ImmunoOncology
Oct 26, 2018
streetinsider
Press Release: Asterias : Immunomic Therapeutics Senior Director of Corporate Development to Present at Precision Lung Cancer World R&D Summit
Oct 01, 2018
FirstWord Pharma
Asterias: Asterias Biotherapeutics Announces Facilities and IP License Option Agreements
Sep 20, 2018
GlobeNewswire
Press Release: Asterias : FDA Accepts Asterias Biotherapeutics' Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program
Sep 12, 2018
Silver Investing News
Asterias: Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
Sep 04, 2018
GlobeNewswire
Press Release: Asterias : Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
